Details

Autor(en) / Beteiligte

• Mensa Vendrell, Mireia
• Tasias Pitarch, Maria
• Salavert Lletí, Miguel
• Calabuig Muñoz, Eva
• Morata Ruiz, Laura
• Castells Lao, Genís
• López Suñé, Ester
• Mensa Pueyo, Jose
• Oltra Sempere, Maria Rosa
• Pedro-Botet Montoya, Maria-Luisa
• Isernia, Valentina
• Reynaga Sosa, Esteban Alberto
• Moreno Nuñez, Leonor
• Pasquau Liaño, Juan
• Sequera Arquelladas, Sergio
• Yuste Ara, José Ramón
• Soriano Viladomiu, Alex

Titel

Safety and Tolerability of More than Six Days of Tedizolid Treatment

Ist Teil von

• Antimicrobial agents and chemotherapy, 2020-06, Vol.64 (7)

Ort / Verlag

United States: American Society for Microbiology

Erscheinungsjahr

2020

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Tedizolid has demonstrated its efficacy and safety in clinical trials; however, data concerning its tolerability in long-term treatments are scarce. The aim of the study was to assess the indications and to describe the long-term safety profile of tedizolid. A multicentric retrospective study of patients who received tedizolid for more than 6 days was conducted. Adverse events (AEs) were identified from patients' medical records and laboratory data. The World Health Organization causality categories were used to discern AEs that were probably associated with tedizolid. Eighty-one patients, treated with tedizolid 200 mg once daily for a median (interquartile range [IQR]) duration of 28 (14 to 59) days, were included; 36 (44.4%) had previously received linezolid. The most common reasons for selecting tedizolid were to avoid linezolid potential toxicities or interactions (53.1%) or due to previous linezolid-related toxicities (27.2%). The most common indications were off-label, including prosthetic joint infections, osteomyelitis, and respiratory infections (77.8%). Overall, 9/81 patients (11.1%) experienced a probably associated AE. Two patients (2.5%) developed gastrointestinal disorders, 1 (1.2%) developed anemia, and 6 developed thrombocytopenia (7.4%) after a median (IQR) duration of treatment of 26.5 (17 to 58.5) days. Four (5%) patients discontinued tedizolid due to AEs. Among 23 patients with chronic renal failure (CRF), the rate of myelotoxicity was 17.4%, and only 8.7% had to stop tedizolid; 20 out of 22 with previous linezolid-associated toxicity had no AE. Long-term tedizolid treatments had good tolerance with rates of gastrointestinal AE and hematological toxicity lower than those reported with linezolid, particularly in patients with CRF and in those with a history of linezolid-associated toxicity.